ClinicalTrials.Veeva

Menu

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Novartis logo

Novartis

Status and phase

Terminated
Phase 2

Conditions

Diabetic Gastropathy

Treatments

Drug: Tegaserod

Study type

Interventional

Funder types

Industry

Identifiers

NCT00142974
CHTF919G2203

Details and patient eligibility

About

This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years
  • GI symptoms for at least 2 months before entering study

Exclusion criteria

  • Very high body weight
  • Significant diarrhea
  • Ulcers

Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems